Association Between State Medicaid Policies and Accrual of Black or Hispanic Patients to Cancer Clinical Trials

被引:1
|
作者
Schpero, William L. [1 ,2 ]
Takvorian, Samuel U. [3 ,4 ,5 ]
Blickstein, Daniel [6 ]
Shafquat, Afrah [6 ]
Liu, Jingshu [6 ]
Chatterjee, Arnaub K. [7 ]
Lamont, Elizabeth B. [6 ]
Chatterjee, Paula [4 ,5 ]
机构
[1] Cornell Univ, Weill Med Coll, Dept Populat Hlth Sci, Div Hlth Policy & Econ, New York, NY 14850 USA
[2] Cornell Univ, Ctr Hlth Equ, New York, NY 14850 USA
[3] Univ Penn, Perelman Sch Med, Div Hematol & Oncol, Philadelphia, PA USA
[4] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA USA
[5] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA USA
[6] Dassault Syst Co, Medidata AI, New York, NY USA
[7] TriNetX, Cambridge, MA USA
关键词
INSURANCE-COVERAGE; INCOME LEVEL; PARTICIPATION; BARRIERS; ENROLLMENT; IMPACT;
D O I
10.1200/JCO.23.01149
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSEIt is unknown whether Medicaid expansion under the Affordable Care Act (ACA) or state-level policies mandating Medicaid coverage of the routine costs of clinical trial participation have ameliorated longstanding racial and ethnic disparities in cancer clinical trial enrollment.METHODSWe conducted a retrospective, cross-sectional difference-in-differences analysis examining the effect of Medicaid expansion on rates of enrollment for Black or Hispanic nonelderly adults in nonobservational, US cancer clinical trials using data from Medidata's Rave platform for 2012-2019. We examined heterogeneity in this effect on the basis of whether states had pre-existing mandates requiring Medicaid coverage of the routine costs of clinical trial participation.RESULTSThe study included 47,870 participants across 1,353 clinical trials and 344 clinical trial sites. In expansion states, the proportion of participants who were Black or Hispanic increased from 16.7% before expansion to 17.2% after Medicaid expansion (0.5 percentage point [PP] change [95% CI, -1.1 to 2.0]). In nonexpansion states, this proportion increased from 19.8% before 2014 (when the first states expanded eligibility under the ACA) to 20.4% after 2014 (0.6 PP change [95% CI, -2.3 to 3.5]). These trends yielded a nonsignificant difference-in-differences estimate of 0.9 PP (95% CI, -2.6 to 4.4). Medicaid expansion was associated with a 5.3 PP (95% CI, 1.9 to 8.7) increase in the enrollment of Black or Hispanic participants in states with mandates requiring Medicaid coverage of the routine costs of trial participation, but not in states without mandates (-0.3 PP [95% CI, -4.5 to 3.9]).CONCLUSIONMedicaid expansion was not associated with a significant increase in the proportion of Black or Hispanic oncology trial participants overall, but was associated with an increase specifically in states that mandated Medicaid coverage of the routine costs of trial participation.
引用
收藏
页码:3238 / 3246
页数:10
相关论文
共 50 条
  • [1] Effect of state-mandated insurance coverage on accrual to community cancer clinical trials
    Ellis, Shellie D.
    Carpenter, William R.
    Minasian, Lori M.
    Weiner, Bryan J.
    CONTEMPORARY CLINICAL TRIALS, 2012, 33 (05) : 933 - 941
  • [2] Accrual and retention of diverse patients in psychosocial cancer clinical trials
    Hanvey, Grace Ann
    Padron, Adaixa
    Kacel, Elizabeth L.
    Cartagena, Gabriel
    Bacharz, Kelsey C.
    McCrae, Christina S.
    Robinson, Michael E.
    Waxenberg, Lori B.
    Antoni, Michael H.
    Berry, Richard B.
    Schultz, Gregory S.
    Castagno, Jacqueline
    Pereira, Deidre B.
    JOURNAL OF CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 6 (01)
  • [3] Strengthening accrual to cancer clinical trials
    Trimble, Edward L.
    Denicoff, Andrea M.
    Abrams, Jeffrey S.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : 291 - 292
  • [4] Promoting Accrual of Older Patients with Cancer to Clinical Trials: An Alliance for Clinical Trials in Oncology Member Survey (A171602)
    Freedman, Rachel A.
    Dockter, Travis J.
    Lafky, Jacqueline M.
    Hurria, Arti
    Muss, Hyman J.
    Cohen, Harvey J.
    Jatoi, Aminah
    Kemeny, M. Margaret
    Ruddy, Kathryn J.
    ONCOLOGIST, 2018, 23 (09) : 1016 - 1023
  • [5] Conceptual Model for Accrual to Cancer Clinical Trials
    Lee, Simon J. Craddock
    Murphy, Caitlin C.
    Geiger, Ann M.
    Gerber, David E.
    Cox, John V.
    Nair, Rasmi
    Skinner, Celette Sugg
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (23) : 1993 - +
  • [6] Strategies for increasing accrual in cancer clinical trials: What is the evidence?
    Michaels, Margo
    Weiss, Elisa S.
    Sae-Hau, Maria
    Illei, Dora
    Lilly, Bethany
    Szumita, Leah
    Connell, Brian
    Lee, Marialanna
    Cooks, Eric
    McPheeters, Melissa
    CANCER MEDICINE, 2024, 13 (10):
  • [7] Interventions to increase racial and ethnic minority accrual into cancer clinical trials: A systematic review
    Nouvini, Rosa
    Parker, Patricia A.
    Malling, Charlotte D.
    Godwin, Kendra
    Costas-Muniz, Rosario
    CANCER, 2022, 128 (21) : 3860 - 3869
  • [8] Socioeconomic and Clinical Factors Are Key To Uncovering Disparity in Accrual Onto Therapeutic Trials for Breast Cancer
    Behrendt, Carolyn E.
    Hurria, Arti
    Tumyan, Lusine
    Niland, Joyce C.
    Mortimer, Joanne E.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2014, 12 (11): : 1579 - 1585
  • [9] Increasing accrual of minority patients in breast cancer clinical trials
    Trant, Amelia A.
    Walz, Lucas
    Allen, Whitney
    DeJesus, Jose
    Hatzis, Christos
    Silber, Andrea
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 184 (02) : 499 - 505
  • [10] Medicaid Expansion of the Patient Protection and Affordable Care Act and Participation of Patients With Medicaid in Cancer Clinical Trials
    Unger, Joseph M.
    Xiao, Hong
    Vaidya, Riha
    LeBlanc, Michael
    Hershman, Dawn L.
    JAMA ONCOLOGY, 2023, 9 (10) : 1371 - 1379